Prostatype Genomics AB (publ)
STO: PROGEN.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Fredrik Rickman
- Employees
- 6
- Headquarters
- Solna, Sweden
- IPO year
- 2020
- Market cap
- SEK 24.4M
- Website
- https://www.prostatypegenomics.com
Loading PROGEN…
Loading profile data…Frequently asked questions about PROGEN
What does Prostatype Genomics AB (publ) (PROGEN.ST) do?
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides...
Where does PROGEN.ST trade?
Prostatype Genomics AB (publ) (PROGEN.ST) trades on the Stockholm Stock Exchange.
What sector is PROGEN.ST in?
Prostatype Genomics AB (publ) (PROGEN.ST) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Prostatype Genomics AB (publ)?
Fredrik Rickman is the chief executive officer of Prostatype Genomics AB (publ) (PROGEN.ST).
Where is Prostatype Genomics AB (publ) headquartered?
Prostatype Genomics AB (publ) is headquartered in Sweden.
Does PROGEN.ST pay a dividend?
Prostatype Genomics AB (publ) (PROGEN.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PROGEN.ST go public?
Prostatype Genomics AB (publ) (PROGEN.ST) completed its initial public offering in 2020.